Green Cross And MNC-Linked Daewoong Stand Out In Korea's Sluggish 3rd Quarter
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's top five pharma companies - excluding Green Cross and Daewoong Pharmaceutical - posted sluggish sales in the third quarter, most of them still finding ways to cope with the government's tightening grip on their business practices
You may also be interested in...
Korean Pharma Earnings Roundup: Companies Struggled In First Quarter Because of April Price Cuts And Tightened Regulatory Grip On Rebates
As widely expected, top Korean companies were badly hit during the first quarter by April price cuts and a continuing government crackdown on rebates.
Korean Analysts Retain Optimism For Daewoong Pharmaceutical On Early Pipeline and In-licensing
SEOUL - Daewoong Pharmaceutical has beefed up its product lineup and increased R&D investment for high-growth therapeutic areas, which has brightened the company's outlook in the eyes of some Korean analysts despite stronger generics competition in 2011
Korean Analysts Retain Optimism For Daewoong Pharmaceutical On Early Pipeline and In-licensing
SEOUL - Daewoong Pharmaceutical has beefed up its product lineup and increased R&D investment for high-growth therapeutic areas, which has brightened the company's outlook in the eyes of some Korean analysts despite stronger generics competition in 2011